Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954137 | 0.82 | MAPK1 (0.53) | MAPK1ALDH1A1KDM4EHPGDCA1 | |
| SCHEMBL15309568 | 0.81 | MAPK1 (0.47) | MAPK1ALDH1A1KDM4EHPGDCA1 | |
| SCHEMBL31056870 | 0.80 | ALDH1A1 (0.48) | MAPK1ALDH1A1KDM4EMAP2K4HPGD | |
| SCHEMBL29324953 | 0.80 | ALDH1A1 (0.48) | MAPK1ALDH1A1KDM4EMAP2K4HPGD | |
| SCHEMBL837412 | 0.79 | MAPK1 (0.46) | MAPK1ALDH1A1KDM4EHPGDCA1 | |
| SCHEMBL15309658 | 0.77 | MAPK1 (0.44) | MAPK1ALDH1A1KDM4EHPGDCA1 | |
| SCHEMBL2952102 | 0.77 | MAPT (0.51) | MAPK1ALDH1A1KDM4EMAP2K4CA1 | |
| SCHEMBL15907818 | 0.76 | KDM4E (0.50) | ALDH1A1KDM4ECA1CA2CA12 | |
| SCHEMBL29598250 | 0.76 | MAPK1 (0.61) | MAPK1ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL31056701 | 0.75 | TDP1 (0.50) | MAPK1ALDH1A1KDM4EHPGDCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | disclosed |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3443958-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| EP-3034075-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9944645-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2057164-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | MAPK1 216/4885ALDH1A1 2912/4885KDM4E 857/4885 |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | MAPK1 90/4885ALDH1A1 1368/4885KDM4E 1073/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | MAPK1 87/4885ALDH1A1 1246/4885KDM4E 1036/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MAPK1 90/4885ALDH1A1 1368/4885KDM4E 1073/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | MAPK1 87/4885ALDH1A1 1246/4885KDM4E 1036/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | MAPK1 90/4885ALDH1A1 1368/4885KDM4E 1073/4885 |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | MAPK1 87/4885ALDH1A1 1246/4885KDM4E 1036/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MAPK1 90/4885ALDH1A1 1368/4885KDM4E 1073/4885 |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | MAPK1 87/4885ALDH1A1 1246/4885KDM4E 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.